10-Q · July 20, 2026
Danaher delivered Q2 revenue of $6.265 billion, up 5.5% year over year and 5.3% sequentially, supported by broad Life Sciences and Biotechnology growth and the Masimo acquisition. GAAP EPS increased to $1.23 from $0.77…
Earnings analysis · 10-Q
DHR earnings analysis
Filed October 20, 2026 · Our reading of the company's report
The latest report
The supplied portion of Danaher’s Q3 2026 10-Q does not contain the financial statements or MD&A needed to assess revenue, margins, EPS, segment trends, balance-sheet movements, or cash flow; those metrics are therefore…
Read full summary
The supplied portion of Danaher’s Q3 2026 10-Q does not contain the financial statements or MD&A needed to assess revenue, margins, EPS, segment trends, balance-sheet movements, or cash flow; those metrics are therefore unavailable. Controls were effective as of September 25, 2026, and the company made no share repurchases during the quarter. The principal disclosed change is a new military-conflict risk factor covering 2026 geopolitical disruptions, while CEO succession became effective October 1, 2026.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Internal controls remained effective
Management concluded that disclosure controls and procedures were effective as of September 25, 2026, and reported no changes in internal control that materially affected, or were reasonably likely to materially affect, reporting controls during the quarter.
-
No share repurchases in the quarter
Danaher repurchased 0 shares during the three-month period ended September 25, 2026, preserving cash for other uses.
-
Repurchase funding remains flexible
The company expects any future stock repurchases to be funded with available cash balances or debt proceeds; no repurchase amount was provided.
-
Leadership transition completed
CEO succession became effective October 1, 2026, with Julie Sawyer Montgomery succeeding Rainer M. Blair; the filing includes multiple transition and compensation-related agreements dated August 3, 2026.
What to watch
-
Military conflict and geopolitical exposure
Danaher added a risk factor covering military conflicts during 2026, including conflicts across multiple Middle Eastern countries. The filing cites potential sanctions, supply-chain disruption, energy-cost increases, inflation, capital-markets volatility, and increased cyber-attacks; environmental proceedings with governmental entities are separately disclosed at a $1 million monetary-sanction threshold.
-
Planned insider share sales
Rainer M. Blair adopted a Rule 10b5-1 plan on August 7, 2026, covering sales through February 6, 2027 of up to 60,015 shares. This may increase potential insider-sale overhang during the leadership transition.
Management's outlook
The supplied 10-Q excerpt does not include quantitative revenue, EPS, margin, or cash-flow outlook. Numeric guidance is therefore not available from the provided filing text.
Earlier filings 2
10-Q · April 20, 2026
Danaher reported Q1 sales of $5,951 million, up $210 million (+3.7%) versus the year-ago quarter but down $889 million (-13.0%) sequentially. Gross profit was $3,591 million (gross margin ~60.35%) with operating profit…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.